Publisher
Springer Berlin Heidelberg
Reference40 articles.
1. Adhoute G., Andreassian B., Boccalon H., Cloarec M., Di Maria G. et al. (1990): Treatment of stage II chronic arterial disease of the lower limbs with the serotonergic antagonist naftidrofuryl: results after 6 months of a controlled, multicenter study. J. Cardiovasc. Pharmacol. 16 (Suppl. 3): S75–S80.
2. Adhoute G., Bacourt F., Barral M., Cardon J.M., Chevalier J.M. et al. (1986): Naftidrofuryl in chronic arterial disease. Results of a six month controlled multicenter study using naftidrofuryl tablets 200 mg. Angiology 37: 160–167.
3. Arzneimittelkommission der Deutschen Apotheker (1995): Naftidrofuryl Infusionslösung. Pharmazeut. Ztg. 140: 2222.
4. Barradell L.B., Brogden R.N. (1996): Oral naftidrofuryl. A review of its pharmacology and therapeutic use in the management of peripheral occlusive arte rial disease. Drugs Aging 8: 299–322.
5. Bauer U. (1984): 6-Month double-blind randomised clinical trial of ginkgo biloba extract versus placebo in two parallel groups in patients suffering from peripheral arterial insufficiency. Arzneim. Forsch. 34: 716–720.